Psoriatic Arthritis

Psoriatic Arthritis

Psoriatic Arthritis

The RELIEF Initiative – Managing Psoriatic Arthritis in Specialty Practice: New Therapies, Guidelines and Treatment Targets During the COVID-19 Pandemic – Daniel Furst, MD and Andreas Reimold, MD

Calendar
When:
March 3, 2021 @ 7:00 pm – 8:30 pm
2021-03-03T19:00:00-05:00
2021-03-03T20:30:00-05:00
Summit Meetings

Wednesday, March 3, 2021

7:00PM – 8:30PM ET

Please note this virtual program is 7:00PM Eastern, 6:00PM Central, 5:00PM Mountain and 4:00PM Pacific.

Faculty

Daniel E. Furst, MD
Professor of Rheumatology and Medicine
University of California, Los Angeles, CA
University of Washington, Seattle, WA
University of Florence, Florence, Italy

Andreas Reimold, MD
Professor, Rheumatic Diseases Division
Department of Internal Medicine
University of Texas Southwestern Medical Center
Dallas, Texas

View Activity

Leave a Reply

Your email address will not be published. Required fields are marked *

This activity is provided by Med Learning Group.
This activity is co-provided by Ultimate Medical Academy/ Complete Conference Management (CCM). 
This activity is supported by an educational grant from Lilly.

mlg-logos-2022
Copyright © 2024 Med Learning Group. Built by Divigner. All Rights Reserved.
Home
Clinical Toolkit
PsA and COVID-19
Diagnosis
Treatment Considerations
Resources
Patient Toolkit
What Are PsA and COVID-19
Living With PsA
FAQ
Resources
Can We Talk?
CME Activities
Poster Portal
Animations
About Us
Contact

Updates in the Treatment and Prevention of COVID-19

EUA of Bamlanivimab Plus Etesevimab Expanded to Include Younger Pediatric Patients

The emergency use authorization (EUA) for bamlanivimab plus etesevimab now includes an indication for treatment and post-exposure prophylaxis for children and newborn babies who are at high risk for severe disease. The expansion of the EUA is supported by a trial of 125 pediatric patients with at least one risk factor for severe illness; the study had safety and efficacy data similar to findings for adolescents and adults.

For more information visit www.fda.gov/news-events/press-announcements/fda-expands-authorization-two-monoclonal-antibodies-treatment-and-post-exposure-prevention-covid-19

 

Oral Antiviral Therapies With Emergency Use Authorization (EUA) for COVID-19

Two new oral antiviral therapies received emergency use authorization (EUA) for COVID-19: Paxlovid™ (nirmatrelvir tablets and ritonavir tablets, co-packaged) and molnupiravir. Both therapies are authorized for the treatment of mild-to-moderate COVID-19 in certain people who are at high risk of progressing to severe illness.

In the EPIC-HR clinical trial, nirmatrelvir/ritonavir significantly reduced the risk of hospitalization or death from any cause by 88% compared with placebo. This treatment is indicated for adults and pediatric patients, 12 years of age and older who weigh at least 40 kilograms. Side effects include an impaired sense of taste, diarrhea, high blood pressure, and muscle aches. The safety and effectiveness of this combination therapy continue to be evaluated.

The main outcome measure of the MOVe-OUT trial of molnupiravir was the percentage of people who were hospitalized or died due to any cause during 29 days of follow-up. Compared with 9.7% of people who received placebo, 6.8% of those in the molnupiravir group were hospitalized or died. One person who received molnupiravir died versus nine people in the placebo group. Molnupiravir is not recommended for pregnant women or for those people younger than 18 years of age because of its effect on bone and cartilage growth.

For more information regarding the EUA for these oral antivirals, visit the following FDA URLs:

www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19

www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-treatment-covid-19-certain

 

FDA Authorized Emergency Use Authorization (EUA) for Long-Acting Monoclonal Antibodies as Pre-Exposure Prophylaxis of COVID-19

Evusheld™ (tixagevimab co-packaged with cilgavimab and administered together) has been granted EUA for the prevention of COVID-19 in certain people with compromised immune systems or with a history of severe adverse reactions to a COVID-19 vaccine or any of its components. This combination is not meant to be a substitute for vaccination for those who have no contraindications to a COVID-19 vaccine.

The PROVENT clinical trial demonstrated a 77% reduction in the risk of developing COVID-19 compared with placebo, and protection appears to have been maintained through six months. Safety and efficacy of the tixagevimab/cilgavimab combination continues to be investigated.

For more information, visit www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-new-long-acting-monoclonal-antibodies-pre-exposure